Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Meta-Lina Spohn has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    PKLM: A flexible MCAR test using Classification

    by Meta-Lina Spohn, Jeffrey Näf, Loris Michel, Nicolai Meinshausen

    We develop a fully non-parametric, easy-to-use, and powerful test for the missing completely at random (MCAR) assumption on the missingness mechanism of a dataset. The test compares distributions of different missing patterns on random projections in the variable space of the data. The distributional differences are measured with the Kullback-Leibler Divergence, using probability Random Forests. We thus refer to it as "Projected Kullback-Leibler MCAR" (PKLM) test. The use of random projections makes it applicable even if very few or no fully observed observations are available or if the number of dimensions is large. An efficient permutation approach guarantees the level for any finite sample size, resolving a major shortcoming of most other available tests. Moreover, the test can be used on both discrete and continuous data. We show empirically on a range of simulated data distributions and real datasets that our test has consistently high power and is able to avoid inflated type-I errors. Finally, we provide an R-package PKLMtest with an implementation of our test.


  • Open Access

    Imputation Scores

    by Jeffrey Näf, Meta-Lina Spohn, Loris Michel, Nicolai Meinshausen

    Given the prevalence of missing data in modern statistical research, a broad range of methods is available for any given imputation task. How does one choose the `best' imputation method in a given application? The standard approach is to select some observations, set their status to missing, and compare prediction accuracy of the methods under consideration of these observations. Besides having to somewhat artificially mask observations, a shortcoming of this approach is that imputations based on the conditional mean will rank highest if predictive accuracy is measured with quadratic loss. In contrast, we want to rank highest an imputation that can sample from the true conditional distributions. In this paper, we develop a framework called "Imputation Scores" (I-Scores) for assessing missing value imputations. We provide a specific I-Score based on density ratios and projections, that is applicable to discrete and continuous data. It does not require to mask additional observations for evaluations and is also applicable if there are no complete observations. The population version is shown to be proper in the sense that the highest rank is assigned to an imputation method that samples from the correct conditional distribution. The propriety is shown under the missing completely at random (MCAR) assumption but is also shown to be valid under missing at random (MAR) with slightly more restrictive assumptions. We show empirically on a range of data sets and imputation methods that our score consistently ranks true data high(est) and is able to avoid pitfalls usually associated with performance measures such as RMSE. Finally, we provide the R-package Iscores available on CRAN with an implementation of our method.


  • Open Access

    Comprehensive Statistical Exploration of Prognostic (Bio-)Markers for Responses to Immune Checkpoint Inhibitor in Patients with Non-Small Cell Lung Cancer

    by Stefanie Hiltbrunner, Meta-Lina Spohn, Ramona Wechsler, Dilara Akhoundova, Lorenz Bankel, Sabrina Kasser, Svenja Bihr, Christian Britschgi, Marloes H. Maathuis, Alessandra Curioni-Fontecedro

    Metastatic non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs) may suffer from heavy side effects and not all patients benefit from the treatment. We conducted a comprehensive statistical analysis to identify promising (bio-)markers for treatment response. We analyzed retrospective data from NSCLC patients treated with ICIs in first- or further-line therapy settings at the University Hospital Zurich. We investigated 16 possible prognostic markers with respect to overall survival, tumor size reduction, and the development of an immune-related adverse event (irAE) and assessed the robustness of our results. For the further-line patient group, the most significant result was that increased basophil counts were associated with increased odds of tumor size reduction within three months and with the development of an irAE. For the first-line patient group, the most significant results were that increased lymphocyte counts, the histology of adenocarcinoma, and the intake of non-steroidal anti-rheumatic drugs (NSAR) were associated with decreased hazards of dying. Our study yielded new hypotheses for predictive (bio-)markers for response to ICIs in NSCLC patients. The possibly beneficial role of high basophil counts is a particularly interesting finding. Our results should be tested on independent data in a prospective fashion.